With the numerous rodent models that followed the discovery of SOD1 (Lutz, 2018), and the more recent emergence of induced MN from ALS patients’ iPSC (Guo et al., 2017), the vast majority of preclinical studies have concentrated on deciphering the mechanisms involved in MN degeneration, implicitly favoring the “dying-back” hypothesis. This evidence concerns the gene SOD1 and amyotrophic lateral sclerosis.